sequanamedical

Commercial stage medical device company utilizing its proprietary **alfa**pump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.

Fast facts

- Founded in 2006
- Headquarters in Ghent, Belgium
- Manufacturing in Zurich, Switzerland
- ~60 employees
- Listed on Euronext Brussels: SEQUA
- Unique **alfa**pump platform
- Novel DSR platform
- Strong IP position
- Global network of KOLs in Europe and North America

Two pillars of growth

alfapump®



Liver Disease (NASH)

- POSEIDON pivotal study ongoing
- Self-commercialisation

alfapump **DSR**®



Heart Failure

- SAHARA DESERT feasibility study ongoing
- Partnering after US efficacy study

Built upon proven European clinical & commercial experience

Liver Disease / NASH

Fluid overload is a fast-growing complication of advanced liver disease driven by NASH-related cirrhosis which is forecast to grow dramatically, in particular in the US.

Heart Failure

Fluid overload is a major clinical complication of heart failure and 40% of heart failure patients on IV loop diuretics are poorly controlled with diurectics.

Strong outlook for value drivers



Note: Presented timelines are subject to further developments related to the COVID-19 pandemic

For more information, visit **www.sequanamedical.com or contact IR@sequanamedical.com**

Regulatory disclaimer: The **alfa**pump® system is currently not approved in the United States or Canada. In the United States and Canada, the **alfa**pump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. DSR® therapy is currently not approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the **alfa**pump® system in Europe, the United States or Canada.

Source: Testani, Circ Heart Failure, 2014 & 2016 **DSR**: Direct Sodium Removal; **NASH**: Non-alcoholic steatohepatitis; **FPI**: First Patient In; **LPI**: Last Patient In

Note: **alfa**pump® is a registered trademark. DSR® and **alfa**pump DSR® are registered trademarks in the Benelux.

December 2021



sequanamedical

alfapump platform: using the bladder to manage fluid overload

The **alfa**pump is a subcutaneously implanted battery-powered pump that automatically and continuously pumps fluid from the abdominal cavity into the bladder, where the body eliminates the fluid naturally. The patient charges the **alfa**pump wirelessly through the skin using a hand-held device.

1. Automatic and continuous removal of fluid from the abdomen
2. Fluid is pumped into bladder
3. Fluid leaves the body through normal urination
4. Wireless charging and communication for monitoring

alfapump: proven step change for treatment of refractory liver ascites and malignant ascites

In the US, the company's key growth market, the **alfa**pump has been granted **breakthrough device designation by the FDA** for recurrent or refractory liver ascites.

The attractiveness of the US market for the **alfa**pump is driven by the increasing prevalence of NASH-related cirrhosis, creating a much larger and more dynamic market opportunity for the **alfa**pump than the traditional cirrhosis markets caused by alcoholic liver disease and hepatitis.

The North American pivotal study (POSEIDON) in recurrent and refractory ascites due to liver cirrhosis is currently underway, and is intended to support a commercial marketing application of the **alfa**pump in the US and Canada. Interim data on 26 patients from the Roll-In Cohort showed positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life. All patients have been enrolled in the study and primary endpoint reporting is planned for Q4 2022.

In the EU, the **alfa**pump is CE-marked for the treatment of refractory ascites due to liver cirrhosis and malignant ascites and is included in key clinical practice guidelines. Over 850 **alfa**pump devices have been implanted to date.

alfapump DSR: potential chronic therapy for heart failure patients not well controlled on diuretics

The **alfa**pump DSR is built upon the proven **alfa**pump platform, to deliver a fully implanted system for Direct Sodium Removal (DSR) therapy, the company's proprietary therapy for the management of fluid overload in heart failure.

DSR therapy involves the use of the peritoneal cavity for the removal of sodium via diffusion into a sodium-free solution (DSR infusate). The **alfa**pump pumps the sodium-rich fluid into the bladder where it is urinated away.

Clinical proof-of-concept data from a first-in-human single dose DSR study have been published in the high impact cardiovascular journal, *Circulation*.

A repeated dose **alfa**pump DSR study (RED DESERT) in stable diuretic-resistant heart failure patients has demonstrated that repeated DSR therapy is able to both manage the fluid and sodium balance of these patients as well as restore their diuretic response and cardio-renal status. The SAHARA DESERT study of **alfa**pump DSR in decompensated heart failure patients is currently ongoing. Interim results indicated a safe, effective and rapid elimination of persistent congestion and restoration of euvolemia, together with a considerable benefit in cardio-renal status and a dramatic improvement in diuretic responsiveness. Top-line data are expected in H2 2022.



DSR therapy directly removes the sodium

Body eliminates excess fluid to restore the balance